Last reviewed · How we verify
Neuropathic diabetic ulcer - foot — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Regranex | BECAPLERMIN | Omj Pharmaceuticals | Human Platelet-derived Growth Factor | Platelet-derived growth factor receptor | 1997-01-01 | |
| Regranex | Regranex | Solsys Medical LLC | Platelet-derived growth factor receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Omj Pharmaceuticals · 1 drug in Neuropathic diabetic ulcer - foot
- Solsys Medical LLC · 1 drug in Neuropathic diabetic ulcer - foot
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Neuropathic diabetic ulcer - foot:
- Neuropathic diabetic ulcer - foot treatment updates — RSS
- Neuropathic diabetic ulcer - foot treatment updates — Atom
- Neuropathic diabetic ulcer - foot treatment updates — JSON
Cite this brief
Drug Landscape (2026). Neuropathic diabetic ulcer - foot — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/neuropathic-diabetic-ulcer-foot. Accessed 2026-06-10.
Related
- Neuropathic diabetic ulcer - foot full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing